Evolus, Inc. announced it has further strengthened and diversified its Board with the appointments of Peter Farrell, Ph.D. and Karah Parschauer, J.D. effective July 15, 2019. Dr. Peter Farrell is an industry veteran with extensive public company experience having successfully taken companies from inception through full scale commercialization. He is the Founder and current Chairman of the Board of ResMed, where he served as its Chief Executive Officer until 2014. Karah Parschauer has extensive experience leading biotech companies through various phases of growth and transformation. Ms. Parschauer is currently Executive Vice President, General Counsel and Secretary to the Board of Directors at Ultragenyx Pharmaceutical. Ms. Parschauer currently serves on the board of Arcturus Therapeutics Ltd.
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology in regulatory development. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins, and injectable dermal fillers.